32nd week of 2022 patent applcation highlights part 30 |
Patent application number | Title | Published |
20220251497 | MICROFLUIDIC CHIP SUITABLE FOR CAPTURING CIRCULATING TUMOUR CELLS - A microfluidic chip capable of being used for capturing target particles, the chip comprising a convergence and shunt unit, the convergence and shunt unit being capable of converging target particles in a liquid sample to the centre of a liquid flow, and simultaneously splitting off a certain proportion of the liquid flow that does not contain target particles, thereby effectively reducing the flow and speed of the liquid flow inputted to the chip; when used for capturing target particles, the chip also comprises a capturing unit, and implements capture of the target particles by means of the capturing unit. | 2022-08-11 |
20220251498 | FACILITIES AND PROCESSES TO PRODUCE BIOTHERAPEUTICS - The concepts described herein are directed to implementations of production facilities that can produce molecules used to treat biological conditions, such as biotherapeutics. The biotherapeutics can include various molecules, such as proteins, enzymes, and antibodies. The production facilities can include a number of separate modular cleanrooms that comprise particular pieces of equipment to perform one or more aspects of the processes used to manufacture biotherapeutics. The modular cleanrooms are arranged such that material that is produced by the equipment of one modular cleanroom can be transferred to another modular cleanroom for additional processing. Additionally, systems and processes are described to generate models using machine learning techniques, where the models can be used to predict productivity and/or efficiency metrics for production lines of biotherapeutics. Further, models can be generated to control the operation of pieces of equipment included in the production lines. | 2022-08-11 |
20220251500 | PHOTOSYNTHETIC PROTEIN SECRETION PLATFORM - Disclosed herein are methods and compositions for implementing a photosynthetic protein secretion platform. | 2022-08-11 |
20220251501 | METHOD FOR PREPARING FERMENTED SOY PRODUCT USING BACILLUS AMYLOLIQUEFACIENS - The present disclosure relates to a method for preparing a fermented soy product comprising: inoculating a | 2022-08-11 |
20220251502 | METHODS FOR REDUCING THE OXIDATION LEVEL OF CYSTEINE RESIDUES IN A SECRETED RECOMBINANTLY-EXPRESSED PROTEIN DURING CELL CULTURE - The present disclosure relates to methods for reducing the oxidation level of cysteine residues in recombinant polypeptides such as anti-IL-17 antibodies during cell culture (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of recombinant polypeptides such as anti-IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab. Also provided are purified preparations of recombinant polypeptides produced by such methods wherein the level of active recombinant polypeptide in the preparation is high. | 2022-08-11 |
20220251503 | ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANS - The present disclosure is directed to methods for the formation and production of renewable muscle and/or fat primary cell lines, immortalized cell lines, and stem cell lines from shrimp, prawn, crab, crayfish, and/or lobster species and the cell lines themselves as well as human and animal consumable meat products produced therefrom. | 2022-08-11 |
20220251504 | FUNCTIONAL ASTROCYTES DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAME - Described is the efficient and robust generation and isolation of functional astrocytes from pluripotent stem cells (PSCs). The methodology provided recapitulate the major steps of oligodendrocyte differentiation into mixed cell populations and subsequent isolation of astrocytes from the mixed cell populations. | 2022-08-11 |
20220251505 | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS - Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, β2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and/or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions. | 2022-08-11 |
20220251506 | METHOD FOR INDUCING ANTIGEN SPECIFIC CD8 POSITIVE T CELLS - Provided is a method for inducing CD4 | 2022-08-11 |
20220251507 | METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE - Described herein are methods of producing enriched target cell populations that are susceptible to genetic engineering. | 2022-08-11 |
20220251508 | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY - The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7. | 2022-08-11 |
20220251509 | PLATFORM FOR ACTIVATION AND EXPANSION OF VIRUS-SPECIFIC T-CELLS - Embodiments of the disclosure concern methods and compositions for immunotherapy for diseases and malignancies associated with viruses other than HPV or with non-virus-associated diseases and malignancies, such as wherein the VST encodes a CAR specific for a non-viral cancer and the VST can be stimulated in vitro or in vivo using viruses, viral vaccines or oncolytic viruses. In specific embodiments, methods concern production of immune cells that target one or more antigens of HIV, EBV, CMV, adenovirus, vaccinia virus, and/or VZV, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-2, IL-4, or both. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells. | 2022-08-11 |
20220251510 | METHODS OF MAKING RED BLOOD CELLS AND PLATELETS IN VITRO AND USES THEREOF - Disclosed herein are methods of producing platelets and red blood cells using synthetic biology and uses thereof. The methods disclosed herein can also be used to produce platelets and red blood cells comprising a therapeutic agent. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis various diseases and disorders and be used as a research tool. | 2022-08-11 |
20220251511 | BOVINE MONOCYTE-DERIVED MACROPHAGE IN CULTURE SYSTEM AND METHODS FOR MEASURING INNATE IMMUNITY - The present disclosure provides an in vitro method of generating bovine monocyte-derived macrophages from monocytes that produce nitric oxide and use as an indicator of innate immune response potential. The culture system includes culturing bovine monocytes in serum-free media supplemented with granulocyte-macrophage stimulating factor (GM-CSF) to generate monocyte-derived macrophages that produce nitric oxide. | 2022-08-11 |
20220251512 | SERUM-FREE POLYPEPTIDE COMPOSITION FOR PROMOTING PROLIFERATION OF MESENCHYMAL STEM CELLS - The present invention provides a serum-free polypeptide composition for promoting proliferation of mesenchymal stem cells. The composition mainly comprises: 10-100 μg/L of tripeptide-1; 1-20 μg/L of tripeptide-2, 1-20 μg/L of hexapeptide-9, 1-20 μg/L of palmitoyl hexapeptide-12; and 10-100 μg/L of a laminin-derived peptide. The serum-free polypeptide composition provided in the present disclosure has clear chemical components without animal origins or serum, can achieve rapid proliferation of the mesenchymal stem cells, and maintains the biological characteristics and immunophenotypic stability of the mesenchymal stem cells while solving the problem of the insufficient quantity of cells. | 2022-08-11 |
20220251513 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. | 2022-08-11 |
20220251514 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. | 2022-08-11 |
20220251515 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. | 2022-08-11 |
20220251516 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES - The present disclosure provides methods of producing progenitor cells from induced pluripotent stem cells, wherein the progenitor cells comprise endothelial cells, pericytes, brain microvascular endothelial cells (BMECs), mesenchymal stem cells (MSCs), hematopoietic precursor cells (HPCs), microglia or neural precursor cells (NPCs). | 2022-08-11 |
20220251517 | 3-D HUMAN MODEL OF COMPLEX CARDIAC ARRHYTHMIAS - Various embodiments are described herein for creating a 3D human heart model for modelling arrythmias, wherein the method comprises seeding a structure with a mixture of human cardiomyocytes, cardiac fibroblasts and a fibrin mixture to form cardiac tissue; applying a plating media for settlement and compaction of the cardiac tissue; and adding an arrhythmogenic media to the cardiac tissue, where the arrhythmogenic media comprises methyl-beta cyclodextrin for disrupting calcium signaling. | 2022-08-11 |
20220251518 | HYBRIDOMA, METHOD FOR MAKING THE SAME, MONOCLONAL ANTIBODY, AND METHOD FOR MAKING THE SAME - An object of the present invention is to provide a means that makes it possible to obtain an antibody that specifically binds to the conformational epitope of a protein antigen and to produce a variety of monoclonal antibodies with unique specificity even in the case of conducting a booster. A non-human animal (animal for immunization) is immunized by intradermal administration of a protein antigen, antibody-producing cells are obtained from a regional lymph node corresponding to the administration site for the above antigen in the immunized animal, and a monoclonal antibody is made by hybridoma technology as described above. | 2022-08-11 |
20220251519 | CONCENTRATION MEMBRANE, CONCENTRATION DEVICE, CONCENTRATION SYSTEM, AND CONCENTRATION METHOD FOR BIOLOGICAL PARTICLES, AND METHOD FOR DETECTING BIOLOGICAL PARTICLES - A concentration membrane for use in concentrating biological particles, including: a hydrophilic composite porous membrane including: a porous substrate; and a hydrophilic resin with which at least one main surface and inner surfaces of pores of the porous substrate are coated, the hydrophilic composite porous membrane having a ratio t/x of a membrane thickness t (m) to an average pore diameter x (m), as measured with a perm porometer, of from 50 to 630. A concentration device | 2022-08-11 |
20220251520 | AAV VECTORS PRODUCED BY INSECT CELLS COMPRISING REP52 AND REP78 CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES - The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors. | 2022-08-11 |
20220251521 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS - The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus. | 2022-08-11 |
20220251522 | MATERIALS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SULFATASE ENZYMES - The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention. | 2022-08-11 |
20220251523 | ENGINEERED ACETATE KINASE VARIANT ENZYMES - The present invention provides engineered acetate kinase (AcK) enzymes, polypeptides having AcK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AcK enzymes are also provided. The present invention further provides compositions comprising the AcK enzymes and methods of using the engineered AcK enzymes. The present invention finds particular use in the production of pharmaceutical compounds. | 2022-08-11 |
20220251524 | INHIBITION OF DNA POLYMERASES BY URACIL-DNA GLYCOSYLASE-CLEAVABLE OLIGONUCLEOTIDE LIGANDS - Provided are methods and compositions for activating oligonucleotide aptamer-deactivated DNA polymerases, comprising modifying the aptamer by uracil-DNA glycosylase enzymatic activity to reduce or eliminate binding of the oligonucleotide aptamer to the DNA polymerase, thereby activating DNA synthesis activity of the DNA polymerase in a reaction mixture. Mixtures for use in methods of the invention are also provided. In some aspects, the oligonucleotide aptamers are circular and comprise one or more deoxyuridine nucleotides providing for aptamer-specific recognition and modification of the circular aptamer by the uracil-DNA glycosylase enzymatic activity. Exemplary oligonucleotide aptamers, mixtures and methods employing uracil-DNA glycosylase enzymatic activity are provided. The methods can be practiced using kits comprising a DNA polymerase-binding oligonucleotide aptamer and at least one uracil-DNA glycosylase enzymatic activity having oligonucleotide aptamer-specific recognition to provide for specific modification of the aptamer by the uracil-DNA glycosylase enzymatic activity. | 2022-08-11 |
20220251525 | INHIBITION OF NUCLEIC ACID POLYMERASES BY ENDONUCLEASE V-CLEAVABLE CIRCULAR OLIGONUCLEOTIDE LIGANDS - Provided are methods and compositions for activating oligonucleotide aptamer-deactivated DNA polymerases, comprising cleaving the aptamer by endonuclease V enzymatic activity to reduce or eliminate binding of the oligonucleotide aptamer to the DNA polymerase, thereby activating DNA synthesis activity of the DNA polymerase in a reaction mixture. Mixtures for use in methods of the invention are also provided. The oligonucleotide aptamers of the present invention are circular and comprise one or more deoxyinosine nucleotides providing for aptamer-specific recognition and cleavage of the circular aptamer by the endonuclease V enzymatic activity. Exemplary oligonucleotide aptamers, mixtures and methods employing endonuclease V enzymatic activity are provided. The methods can be practiced using kits comprising a DNA polymerase-binding oligonucleotide aptamer and at least one endonuclease V enzymatic activity having oligonucleotide aptamer-specific recognition to provide for specific cleavage of the aptamer by the endonuclease V enzymatic activity. | 2022-08-11 |
20220251526 | TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOF - The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lyso-somal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lysosomal storage diseases in mammals. | 2022-08-11 |
20220251527 | XYLANASE MUTANT AND ITS PREPARATION METHOD AND APPLICATION - The present invention discloses a kind of xylanase mutant and its preparation method and application, which relates to the technical field of genomic engineering and genetic engineering. Such mutant includes one or more mutants obtained by taking xylanase HwXyl10A as female parent to conduct saturation mutagenesis to the site of Gly363. Specifically, relates to obtaining 19 mutants through site-directed mutagenesis, and then conducting yeast expression to them, after that, obtaining two mutants with significantly improved specific activity and thermal stability through screening of thermal stability and catalytic activity; the present invention can significantly improve the thermal stability and catalytic efficiency of xylanase through modifying the site of Gly363, and is of important guiding significance for improving the thermal stability and the catalytic efficiency of the 10th family of xylanases and other glycoside hydrolases as well as lays the foundation for its application in industrial production. | 2022-08-11 |
20220251528 | Alpha-Amylase Variants - The present invention relates to variants of a parent alpha-amylase having an improved wash performance when compared to the parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants, nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and method of producing the variants of the present invention. | 2022-08-11 |
20220251529 | Improved Mannanase Variants - A variant of mannanase is disclosed having at least 90% sequence identity with SEQ ID NO: 1 and a substitution of an amino acid in position 256. An enzyme composition, detergent composition, host cell, animal feed, and feed supplement comprising the present variant are disclosed, as well as methods and uses involving the present variant. | 2022-08-11 |
20220251530 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF - The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit. | 2022-08-11 |
20220251531 | NON-TOXIC PROTEASE HAVING IMPROVED PRODUCTIVITY - The present invention relates to a mutated non-toxic protease in which the amino acid cysteine (Cys) at position 430 of a non-toxic protease represented by the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than cysteine. According to the present invention, it is possible to recover a refolded non-toxic protease from an insoluble fraction from which the non-toxic protease was almost impossible to recover in the prior art, and thus it is possible to produce the non-toxic protease with significantly improved productivity. | 2022-08-11 |
20220251532 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 2022-08-11 |
20220251533 | MODIFIED STRAINS FOR THE PRODUCTION OF RECOMBINANT SILK - Disclosed herein are modified strains for reducing degradation of recombinantly expessed products secreted from a host organism and methods of using the modified strains. In some embodiments, to attenuate a protease activity in | 2022-08-11 |
20220251534 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES - The present disclosure relates to protein sequences which can be used to generate factor Xa proteins and derivatives thereof. The protein sequences include a factor Xa light chain portion, a heavy chain catalytic domain portion, and an activation peptide C-terminal to the heavy chain catalytic domain portion. It is discovered that when an activation peptide (AP) is fused to the C-terminal end of the heavy chain of the factor Xa protein or derivative, the resulting protein can be more efficiently expressed, and the attachment of the activation peptide (AP) to the heavy chain does not affect the activity of the protein. | 2022-08-11 |
20220251535 | AMINOACYL-TRNA SYNTHETASES AND USES HEREOF - The invention relates to aminoacyl-tRNA synthetases that aminoacylate tRNA with 2-Aminoisobutyric acid (Aib), thus enabling the incorporation of the Aib into a growing polypeptide chain during translation, e.g. in eubacterial host cells such as | 2022-08-11 |
20220251536 | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA - Synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) and exhibiting augmented expression in cell culture and/or in a subject are described herein. Adeno-associated viral (AAV) gene therapy vectors encoding synPCCA successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase alpha (Pcca | 2022-08-11 |
20220251537 | METHODS ADN SYSTEMS FOR ISOLATING AND IDENTIFYING NUCLEIC ACID FROM A PLURALITY OF MICROORGANISMS AND VIRUSES - The disclosure relates to laboratory and bioinformatics methods for isolating, detecting, and characterizing microbes in biological samples using metagenomic approaches. | 2022-08-11 |
20220251538 | METHOD FOR REMOVAL OF NUCLEIC ACIDS IMPURITIES FROM LIQUID COMPOSITION COMPRISING GENETICALLY ENGINEERED PARTICLES OR PROTEINS - The present disclosure provides improved methods for purifying recombinant protein, vaccine and gene therapy preparations, such as vectors in a suspension, as well as new means to better assay residual nucleic acids in a composition comprising genetically engineered particles. One aspect of the present disclosure is a method for purifying a liquid composition comprising genetically engineered particles from nucleic acid impurities comprising the steps of (i) adding a Dps protein to the suspension comprising genetically engineered particles, (ii) precipitating a complex comprising the nucleic acid impurities and the Dps protein and (iii) removing the precipitated complex comprising the nucleic acid impurities and Dps protein from the suspension comprising genetically engineered particles. Another aspect of the disclosure is a method to assay nucleic acid impurities in a liquid composition comprising genetically engineered particles or a pharmaceutical composition comprising genetically engineered particles. | 2022-08-11 |
20220251539 | CONCENTRATING BIOLOGICAL COMPONENTS - A biological component concentration fluid assembly includes magnetizing microparticles that are surface-activated to bind with (or are bound to) a biological component; a multi-fluid density gradient column with a first fluid layer, a second fluid layer, and a third fluid layer; and a magnet to attract and draw the magnetizing microparticles from the first fluid layer, through the second fluid layer, and into the third fluid layer. The first fluid layer has a first fluid density, and a second fluid layer has a second fluid density that is greater than the first fluid density, and is positioned beneath the first fluid layer. A third fluid layer has a third fluid density that is greater than the second fluid density and is positioned beneath the second fluid layer. The second and third fluid layers in this example are formulated to interact with the surface of the magnetizing microparticles. | 2022-08-11 |
20220251540 | GENE SITE SATURATION MUTAGENESIS (GSSM) METHOD - Disclosed herein is an improved Gene Site Saturation Mutagenesis (GSSM) method for producing a plurality of modified polynucleotides and/or polypeptides, creating specific changes to a gene, and reassembling mutations or changes at one or more sites. | 2022-08-11 |
20220251541 | DETECTION OF AN ANTIBODY AGAINST A PATHOGEN - Provided herein are methods of detecting an antibody directed against a pathogen and uses thereof. | 2022-08-11 |
20220251542 | NOVEL AAV LIBRARY - An AAV library, comprising AAV variants having an amino acid sequence corresponding to the position amino acids 585 to 597 or 598 of AAV8 or the position amino acids 583 to 595 or 596 of AAV9, and the polynucleotide, host cells, thereof. A method of generating and screening an AAV library and its use. | 2022-08-11 |
20220251543 | METHODS FOR CHARACTERIZING AND ENGINEERING PROTEIN-PROTEIN INTERACTIONS - Characterization of the binding dynamics at the interface between any two proteins that specifically interact plays a role in myriad biomedical applications. The methods disclosed herein provide for the high-throughput characterization of the specific interaction at the interface between two protein binding partners and the identification of functionally significant mutations of one or both protein binding partners. For example, the methods disclosed herein may be useful for epitope and paratope mapping of an antibody-antigen pair, which is useful for the discovery and development of novel therapies, vaccines, diagnostics, among other biomedical applications. | 2022-08-11 |
20220251544 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING AND PREVENTING CANCER - Provided herein, are methods of identifying neoantigens for treating and preventing cancer. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer. | 2022-08-11 |
20220251545 | FRAGMENT-BASED SCREENING TO IDENTIFY SMALL MOLECULES THAT SELECTIVELY BIND RNA - A method is described to define the binding of fragments onto RNA targets and to use this profiling to enable the design of small molecules targeting RNA. The method comprises exposing a labeled RNA target to a small molecule fragment appended with diazirine and an alkyne moiety. Exposure of the compounds to light produce a reactive intermediate from the diazirine moiety that will react with sites in the RNA that are proximal to the small molecule fragments binding site. The RNAs that are reacted with the fragments are captured by using a biotin azide or azide-displaying beads that react with the alkyne moiety in the presence of a Cu(I) catalyst using click chemistry. Biotinylated products are captured with streptavidin resin. The amount of labeled RNA captured by the resin/beads is measured, thereby identifying which fragments bind an RNA target. The binding site of the fragment is determined by RT-PCR. | 2022-08-11 |
20220251546 | METHOD FOR RNA SELECTION AND/OR ENRICHMENT, RNA MOLECULE AND USE THEREOF - A method for RNA selection and/or enrichment, especially with mRNA molecules, from a pool of RNA molecules, the method comprising a step of incubating a sample containing a pool of RNA molecules with an RNA binding protein to form RNA-RNA binding protein complexes, wherein a protein of IFIT family of proteins or its functional variants, homologues or mutants are used as the RNA binding protein. The RNA molecule selected and/or enriched by the method and is used for detection in RNA pathogen-based diagnostic tests and for preparation of libraries for RNA sequencing. | 2022-08-11 |
20220251547 | METHODS AND KITS FOR IDENTIFYING CANCER TREATMENT TARGETS - In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells. | 2022-08-11 |
20220251548 | METHODS FOR PRODUCING A LIBRARY OF BIOLOGICAL MOLECULES - A method for producing a library of biological molecules generally includes providing an engineered polynucleotide vector, amplifying the polynucleotide, and sequencing the library of biological molecules produced. The polynucleotide includes a cloning vector backbone, a recombination site, one or more cloning sites, and a nucleotide sequence template. The nucleotide sequence template includes a coding region, a sequence 5′ to the coding region that is complementary to a portion of the vector backbone, and a sequence 3′ to the coding region that is complementary to a portion of the vector backbone. | 2022-08-11 |
20220251549 | METHOD FOR CONSTRUCTING CAPTURE LIBRARY AND KIT - The present invention provides a method for constructing a capture library, comprising the steps of: (1) obtaining fragmented DNAs; (2) connecting the fragmented DNAs with a Y-shaped linker to obtain a pre-library; (3) hybridizing the pre-library and a hybridization probe in the absence of a blocking sequence to obtain hybridization products; and (4) performing a PCR amplification on the hybridization products to obtain the capture library. The present invention also provides to a kit for carrying out the method. | 2022-08-11 |
20220251550 | METHODS FOR EXTENDING THE REPLICATIVE CAPACITY OF SOMATIC CELLS DURING AN EX VIVO CULTIVATION PROCESS - A product and process for extending the replicative capacity of metazoan somatic cells using targeted genetic amendments to abrogate inhibition of cell-cycle progression during replicative senescence and derive clonal cell lines for scalable applications and industrial production of metazoan cell biomass. An insertion or deletion mutation using guide RNAs targeting the first exon of the transcript encoding each protein is created using CRISPR/Cas9. Targeted amendments result in inactivation of p15 and p16 proteins which increases the proliferative capacity of the modified cell populations relative to their unaltered parental populations. Combining these amendments with ancillary telomerase activity from a genetic construct directing expression of a telomerase protein homolog from a TERT gene, increases the replicative capacity of the modified cell populations indefinitely. One application is to manufacture skeletal muscle for dietary consumption using cells from the poultry species | 2022-08-11 |
20220251551 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY - Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described. | 2022-08-11 |
20220251552 | Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae - The present invention relates to methods and compositions comprising a miR-302 mimic/s for treatment of lung injury. The miRNA-302 mimic/s facilitate host recovery from lung injury caused due to, for example, bacterial pneumonia | 2022-08-11 |
20220251553 | METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION - The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22. | 2022-08-11 |
20220251554 | OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA - This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided. | 2022-08-11 |
20220251555 | O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES - Novel oligonucleotides that are fully chemically stabilized are provided. Methods of using oligonucleotides that are fully chemically stabilized are also provided. | 2022-08-11 |
20220251556 | ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION - Enhanced antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1), leading to modulation of the expression of RTEL1 or modulation of RTEL1 activity are provided. This disclosure relates to the use of enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. This disclosure further relates to the use of the enhanced antisense oligonucleotides targeting RTEL1 for destabilizing cccDNA, such as HBV cccDNA. A pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection is also described. | 2022-08-11 |
20220251557 | METHOD FOR REDUCING TOXICITY OF ANTISENSE NUCLEIC ACIDS - The purpose of the present invention is to reduce the strong hepatotoxicity of antisense nucleic acids that incorporate an artificial nucleobase (e.g., LNA). The present invention provides a bridged antisense nucleic acid for which antisense nucleic acid-induced toxicity is reduced by the supplemental addition to the wing region of a specific artificial nucleobase (e.g., MCA), while retaining the sequence of the antisense nucleic acid and the number of artificial nucleobases (e.g., LNA). The present invention also provides an antisense nucleic acid drug having a remarkably-reduced hepatotoxicity. | 2022-08-11 |
20220251558 | COMPOSITIONS AND METHODS FOR DISRUPTING THE MOLECULAR MECHANISMS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION AND NEURODEGENERATIVE DISEASE - Retrotransposons, operating though human-specific neurological pathways, can contribute to environment, lifestyle, and/or age-related neurodegeneration by disrupting functional mitochondrial populations within neurons. The mitochondrial disruption can occur through a number of retrotransposon-induced mechanisms that can influence the efficient and accurate transcription and/or translation of mitochondrial genes encoded in the nuclear genome, operating primarily through epigenetic processes. Alu element-related conformational changes (both subtle and major) of the outer and inner mitochondrial membrane pores can restrict or prevent the normal translocation of proteins (i.e., TOMM and TIMM complexes), ultimately contributing to mitochondrial stress, mitophagy, inflammation, and neuron and glial cell death. Compositions and methods are provided for mitigating and/or preventing Alu element-induced conformational changes to prevent and/or treat neurodegenerative disease and other diseases and disorders associated with at least one TOMM, TIMM, or APOE isoform including cancer and other inflammatory diseases. | 2022-08-11 |
20220251559 | ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES - Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. | 2022-08-11 |
20220251560 | METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE - Described herein are methods of producing enriched target cell populations that are susceptible to genetic engineering. | 2022-08-11 |
20220251561 | EPH2A APTAMER AND USES THEREOF - The present invention belongs to the field of genetic therapy. In particular, the invention refers to EphA2 specific RNA-based constructs, which are useful for the treatment, prevention and diagnosis of EphA2 expressing cancers. | 2022-08-11 |
20220251562 | Anti-CD3 Aptamers for Use in Cell Targeting and Labeling - High affinity aptamer sequences recognizing CD3 protein complex on cell surfaces are provided. The aptamers can be used as targeting moieties for delivery vehicles or as molecular components for immunotherapy, immunodiagnostics, or for isolating, purifying, or characterizing CD3+ T cells in a subject. | 2022-08-11 |
20220251563 | COMBINATION VECTORS AND METHODS FOR TREATING CANCER - A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid. | 2022-08-11 |
20220251564 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | 2022-08-11 |
20220251565 | Compositions and Methods for Reducing Perineural Invasion and Pain - Provided herein are compositions for reducing regional perineural invasion and pain in a subject. Methods of reducing regional perineural invasion, and associated pain are also described. | 2022-08-11 |
20220251566 | CELLS ENGINEERED FOR OLIGONUCLEOTIDE DELIVERY, AND METHODS FOR MAKING AND USING THEREOF - The present disclosure is directed to genetically modified carrier/donor cells that are engineered to be resistant to its oligonucleotide payload, and methods of delivering an oligonucleotide into a target cell. The disclosure is also directed to methods of treating cancer using the engineered carrier cells of the disclosure. An aspect of this disclosure is directed to engineering carrier cells to be resistant to the detrimental effects of an oligonucleotide. | 2022-08-11 |
20220251567 | METHODS FOR THE TREATMENT OF EPILEPSY - The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA. The present disclosure also relates to a method for treating epilepsy in a subject in need thereof, wherein the method comprises: administering an effective amount of a vector comprising an oligonucleotide encoding an inhibitory RNA that binds (e.g., hybridizes) specifically to Grik2 mRNA and inhibits expression of Grik2 in the subject. | 2022-08-11 |
20220251568 | METHODS AND COMPOSITIONS RELATED TO RNA-TARGETED RHO SMALL GTPase RND3/RhoE THERAPY - Disclosed are RNA inhibitors, such as small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) specific for RND3, alternatively referred to as RhoE. Also disclosed are methods of treating subjects by administering RNA inhibitors. Further disclosed are methods of detecting potential modulators of RND3. | 2022-08-11 |
20220251569 | TREATMENT AND PREVENTION OF DISEASE MEDIATED BY WWP2 - Methods of treating and preventing fibrosis and pathological inflammation through inhibition of WWP2 are disclosed, as well as agents for use in such methods. | 2022-08-11 |
20220251570 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6. | 2022-08-11 |
20220251571 | APTAMER SPECIFICALLY BINDING TO CANCER STEM CELLS, AND USE THEREOF - The present invention relates to aptamers that specifically bind to cancer stem cells. The aptamers according to the present invention specifically bind to cancer stem cells and reduce cell adhesion ability, cell proliferation, drug resistance and cell migration, which are characteristics of cancer stem cells, thus having excellent anticancer effects. Therefore, the aptamer may be used in various ways in the fields of cancer diagnosis, prognosis prediction, and treatment. | 2022-08-11 |
20220251572 | IMMUNE CELLS DEFECTIVE FOR SUV39H1 - The present invention relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The invention also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases. | 2022-08-11 |
20220251573 | RECOMBINANT MICROORGANISMS AND USES THEREFOR - Microorganisms are genetically engineered to produce 3-hydroxypropionate (3-HP). The microorganisms are carboxydotrophic acetogens. The microorganisms produce acetyl-coA using the Wood-Ljungdahl pathway for fixing CO/CO | 2022-08-11 |
20220251574 | CELL CAPABLE OF ACTIVATING IMMUNE SYSTEM, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL - The present invention provides a cell activating the immune system and a pharmaceutical composition containing the cell. According to the present invention, there is provided a mammalian cell having at least one protein selected from the group consisting of E6 protein and E7 protein for early genes of human papillomavirus and a fusion protein of E6 protein and E7 protein, and CD1d protein, wherein the mammalian cell is pulsed with a CD1d ligand. According to the present invention, there are also provided a fusion protein having E7 protein, E6 protein and E7 protein in this order, a nucleic acid encoding the protein and a gene expression vector therefor. | 2022-08-11 |
20220251575 | Modulation of Engineered Immune Cell Receptor Translation Using Noncoding Sequence Elements - Engineered immune cell receptor translation is modulated using heterologous noncoding sequence elements, such as modified eukaryotic initiation factor 3 (eIF3) responsive sites. | 2022-08-11 |
20220251576 | TRANSFECTION METHOD - A novel means for safely and efficiently introducing a target substance such as nucleic acid, protein, or the like into immune cells such as T cell and the like is provided by the present invention. Thus, a system for delivering a target substance into an immune cell, including ultrafine bubble water or ultrafine bubble aqueous solution containing ultrafine bubbles with an average diameter of not more than 200 nm and not containing phospholipid, and an ultrasound generator in combination; a method for increasing the delivery of a nucleic acid or a protein into an immune cell by using the ultrafine bubble water, etc. and ultrasound; and the like are provided. | 2022-08-11 |
20220251577 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF - The present disclosure provides messenger RNAs (mRNAs) with alterations which provide increased endonuclease resistance to the mRNA and methods and uses thereof. | 2022-08-11 |
20220251578 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE - Provided herein are recombinant circular RNA (circRNA) molecules comprising an internal ribosome entry site (IRES) operably linked to a protein-coding nucleic acid sequence. The IRES includes at least one RNA secondary structure element; and a sequence region that is complementary to an 18S ribosomal RNA (rRNA). Methods of producing a protein in a cell using the recombinant circRNA molecules are also provided. | 2022-08-11 |
20220251579 | ENGINEERED BACTERIA FOR PRODUCTION AND RELEASE OF THERAPEUTICS - Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells. | 2022-08-11 |
20220251580 | IMPROVED GENE EDITING SYSTEM - Provided is a gene editing system for editing a target sequence in the genome of a cell, comprising a CRISPR nuclease, a cytosine deaminase, an AP lyase, a guide RNA and optionally an uracil-DNA glycosylase. Also provided are a method of producing a genetically modified cell, and a kit comprising the gene editing system. | 2022-08-11 |
20220251581 | MODIFIED FILAMENTOUS FUNGAL HOST CELL - The present invention relates to phospholipase D-inactivated filamentous fungal cells secreting a polypeptide of interest and methods of producing a secreted polypeptide of interest in said cells as well as methods of producing said cells. | 2022-08-11 |
20220251582 | MODIFIED YEAST AND METHOD FOR INCREASING LYSINE CONTENT IN FERMENTATION CO-PRODUCTS - Described are strains and methods relating to genetically-engineered yeast cells that overproduce lysine in a tunable manner by altering feedback inhibition of the lysine synthetic pathway by way of the LYS20 and LYS21 homocitrate synthase polypeptides. The yeast can be used in a conventional bioethanol production facility to produce alcohol along with increased amounts of lysine, resulting in increased quality and commercial value of fermentation products and co-products, such as animal feed ingredients. | 2022-08-11 |
20220251583 | CANDIDA UTILIS DOUBLE GENE CO-EXPRESSION STRAIN FOR HYDROLYZING PROTEIN COMPONENTS IN KITCHEN WASTE AND CONSTRUCTION METHOD THEREOF - The present invention relates to the fields of genetic engineering and fermentation engineering, and provides a | 2022-08-11 |
20220251584 | INIR6 TRANSGENIC MAIZE - Transgenic INIR6 maize plants comprising modifications of the DP-4114 maize locus which provide for facile excision of the modified DP-4114 transgenic locus or portions thereof, methods of making such plants, and use of such plants to facilitate breeding are disclosed. | 2022-08-11 |
20220251585 | NOVEL PLANT CELLS, PLANTS, AND SEEDS - Disclosed herein are compositions and methods for effecting alterations at a defined location in the genome of a non-epidermal plant cell. Further disclosed are methods for providing plants having a modified phenotype or a modified genome. | 2022-08-11 |
20220251586 | METHODS AND COMPOSITIONS FOR GENERATING COMPLEX TRAIT LOCI - Compositions and methods are provided for stacking multiple independent transgenic loci into the genome of a plant. Compositions include plants, seeds or plant cells comprising at least one transgenic target site and at least one genomic locus of interest integrated at different genomic sites within a genomic window. Plant breeding techniques can be employed such that the transgenic target site and the genomic locus of interest can be bred together. In this way, multiple independent transgene integrations can be generated within a genomic window to create a complex trait locus. The complex trait locus is designed such that the transgenic target sites and/or genomic loci of interest can segregate independently of each other, thus providing the benefit of altering a complex trait locus by breeding-in and breeding-away specific elements. Various methods can also be employed to modify the target sites such that they contain a variety of polynucleotides of interest. | 2022-08-11 |
20220251587 | USE OF MORPHOGENIC FACTORS FOR THE IMPROVEMENT OF GENE EDITING - Methods and compositions are provided for the improvement of double-strand-break-inducing agent activity in eukaryotic cells, through the usage of one or more morphogenic factors or developmental genes. The morphogenic factor may be provided to the same cell or to a different cell than that comprising or receiving the double-strand-break-inducing agent. The morphogenic factor may be provided to a cell as a polynucleotide composition on a recombinant vector, and may be placed on the vector outside of a T-DNA border. The morphogenic factor may be provided via an upregulation of an endogenous gene. The morphogenic factor, or the double-strand-break-inducing agent, may further comprise a cell penetrating peptide. The morphogenic factor may be co-introduced with a vector comprising RepA. | 2022-08-11 |
20220251588 | COMPOSITIONS AND METHODS FOR CHROMOSOME REARRANGEMENT - Methods and compositions for evaluating the efficiency of chromosomal rearrangement are provided. In some examples, systems comprising a first DNA molecule comprising the N-terminal portion of a first split reporter coding sequence linked to the C-terminal portion of a second split reporter coding sequence via a first intron, and a second DNA molecule comprising the N-terminal portion of said second split reporter coding sequence linked to the C-terminal portion of said first split reporter coding sequence via a second intron. The introns comprise at least one target site recognized by a genome editing reagent, such as a recombinase or endonuclease, such that recombination results in expression of the first or second reporter coding sequence following splicing of the introns. | 2022-08-11 |
20220251589 | RHIZOBIAL tRNA-DERIVED SMALL RNAs AND USES THEREOF FOR REGULATING PLANT NODULATION - Rhizobial infection is the key process for initiating symbiotic nitrogen-fixing root nodules in legumes, which requires specific recognition of signal molecules produced by the bacteria and their hosts. Here, it is established that rhizobial tRNA-derived small RNA fragments (tRFs) are crucial signal molecules modulating host nodulation, which uncovers a bacterial small RNA-mediated mechanism for prokaryote-eukaryote interaction. Transgenic plants are also provided that express a construct encoding rhizobial-derived tRNA, which is subsequently cleaved to produce artificial tRFs. Constructs and methods of producing the same are also provided, as well as modifications for repressing a mechanism for the negative regulation of nodulation present within plants. | 2022-08-11 |
20220251590 | INCREASING WATER USE EFFICIENCY IN PLANTS - The invention relates to methods of increasing water use efficiency (WUE) in plants by modulating the stomatal blue light response. The invention further relates to plants having increased WUE, identifying plants with increased WUE and to related methods of increasing drought tolerance and producing food or feed products under water-limited or drought conditions. | 2022-08-11 |
20220251591 | ABIOTIC STRESS TOLERANT PLANTS AND METHODS - Isolated polynucleotides and polypeptides, and recombinant DNA constructs are useful for conferring improved drought tolerance and yield. Compositions (such as plants or seeds) comprise these recombinant DNA constructs; and methods utilize these recombinant DNA constructs. The recombinant DNA constructs comprise a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotides encode drought tolerance polypeptides. | 2022-08-11 |
20220251592 | COLD-TOLERANT PLANT - The present invention relates to the identification and molecular characterization as well as to the use of genes and markers from a chromosomal interval which has a locus for cold tolerance in maize. The invention further relates to the development of molecular markers for assisting in growth, in particular for preventing a fixing of a “selective sweep” in a region with a low recombination rate, and to the provision of transgenic and non-transgenic plants, in particular maize plants, which show a newly mediated or increased cold tolerance. | 2022-08-11 |
20220251593 | GENES AND USES FOR PLANT ENHANCEMENT - Transgenic seed for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein. | 2022-08-11 |
20220251594 | GLUTAMINE SYNTHETASE MUTANT HAVING GLUFOSINATE AMMONIUM RESISTANCE AND APPLICATION THEREOF AND CULTIVATION METHOD THEREFOR - Glutamine synthetase mutant having glufosinate ammonium resistance, application thereof and a cultivation method therefor. Comparing with the reference sequence, the amino acid sequence of the glutamine synthetase mutant has one or a combination of the following mutations: (1) the amino acid of the glutamine synthetase mutant corresponding to amino acid site 59 of the reference sequence is mutated to X | 2022-08-11 |
20220251595 | ENGINEERED ATRLP23 PATTERN RECOGNITION RECEPTORS AND METHODS OF USE - Compositions and methods for enhancing the disease resistance of plants are provided. The invention provides compositions comprising engineered, pattern recognition receptors which comprise one or more domains derived from the receptor-like protein AtRLP23, particularly a leucine-rich repeat domain, and one or more other domains including, for example, a kinase domain from a receptor-like kinase. The compositions further comprise nucleic acid molecules encoding the engineered proteins and plants, plant cells, and other host cells comprising such nucleic acid molecules and/or the engineered proteins. The invention additionally provides methods for making and using the engineered proteins and nucleic acid molecules encoding the engineered proteins. | 2022-08-11 |
20220251596 | INSECT INHIBITORY TOXIN FAMILY ACTIVE AGAINST HEMIPTERAN AND/OR LEPIDOPTERAN INSECTS - The present invention discloses a genus of insect inhibitory proteins that exhibit properties directed to controlling Lepidopteran and/or Hemipteran crop pests, methods of using such proteins, nucleotide sequences encoding such proteins, methods of detecting and isolating such proteins, and their use in agricultural systems. | 2022-08-11 |
20220251597 | INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity. | 2022-08-11 |